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tive to coding practices was also investigated. RESULTS: Over
100 models were implemented. Majority of the models were 
considered acceptable. Unacceptable models were produced for
conditions of low prevalence and ill-deﬁned conditions. Model
performance was also affected by coding practice (e.g. under-
coding for asthma, depression). CONCLUSIONS: A scalable
and automated method for inferring disease descriptions based
on pharmacy claims in a patient was successfully created. Appli-
cation-speciﬁc modiﬁcations to the method need some investi-
gation and are being pursued.
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OBJECTIVES: An implicit assumption in cost-effectiveness
analysis is that the value of the health beneﬁt (e.g., life year or
quality-adjusted life year gained) is directly proportional to the
gain, irrespective of baseline life expectancy. For example, a gain
of 6 months is valued the same, irrespective of whether the base-
line life expectancy is 40 years (e.g., for a healthy, middle-aged
adult) or 6 months (e.g., for a patient with metastatic cancer).
We examined the theoretical and empirical evidence regarding
the validity of this assumption. METHODS: We reviewed the
theoretical and empirical literature on the relationship between
the value of mortality reduction and life expectancy. We focused
our attention on outcome valuation using the willingness-to-pay
(WTP) and quality-adjusted life year (QALY) approaches.
RESULTS: Results of the review suggest that while research has
been conducted on the relationship between health gains and
baseline life expectancy due to age, the relationship between
health gains and baseline life expectancy due to health status
remains largely unexplored. Economic theory suggests that WTP
for risk reductions depends on baseline risk; however, the two
theoretical arguments (i.e., “dead anyway” and proportionality)
as to why this is so lead to opposite conclusions. QALYs are
assumed to be independent of baseline life expectancy, but this
assumption has been challenged by theorists who have proposed
the use of “age-weighted” measures. Empirical studies have
yielded mixed results. Stated and revealed values of life
expectancy gains are often associated with baseline life
expectancy, but the direction of the association is inconsistent.
CONCLUSIONS: The literature gives mixed support for the
assumption implicit in cost-effectiveness analysis that the value
of a survival gain is directly proportional to the gain and inde-
pendent of baseline life expectancy. Comparisons of cost per
QALY across populations with varying life expectancies should
recognize this limitation.
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OBJECTIVES: Discrete choice experiments (DCEs) are choice-
based methods used to estimate utilities. While DCEs are being
used increasingly in health economics, their application to esti-
mating utilities for health states and outcomes is more novel.
Visual analog scaling (VAS) is a well-established rating method
used widely in health care. Previous studies have shown that
DCE and VAS results are highly correlated. This study com-
pares state and attribute utilities for Barthel Index (BI) physical
disability states estimated by DCEs and the VAS method.
METHODS: A convenience sample of 152 subjects (≥ 45 years)
able to answer the 37-question survey was enrolled. Demo-
graphic characteristics, and physical disability and caregiving
histories were collected. The DCE consisted of 13 choice sets.
The VAS exercise used a rating thermometer (0 = worst imagin-
able health state, 20 = best imaginable health state) to rate 14
scenarios. The survey was administered in individual and small
group settings by trained researchers. Utilities for disability states
and attributes were analyzed using ordinary least squares and
probit regressions. Spearman correlations were calculated to
compare utilities and BI scores. RESULTS: Thirty-one percent of
the subjects were male, mean age was 61 years, 88% were Cau-
casian, 60% had more than a high school education, and 63%
were married. The strongest determinants of VAS utilities were
Feeding (p = .002), Continence (p = .003), Mobility (p < .001),
and Bathroom Use (p = .041). Feeding, Bathroom Use and Per-
sonal Care were the strongest determinants of DCE utilities (p <
.001). The relative contribution of Feeding was strongest in the
DCE model. Correlations between VAS and DCE utilities, and
BI scores were 96% and 91%, respectively. The correlation
between VAS and DCE utilities was 94%. CONCLUSIONS:
Although highly correlated, attribute contributions to DCE 
and VAS utilities differed. Subgroup analyses and exploration 
of design issues should help clarify the basis for the model 
differences.
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OBJECTIVES: To investigate characteristics associated with
being a non-trader and differences between trader and non-
trader groups. A limitation of utility elicitation using the Time
Trade-Off (TTO) method is that a substantial minority are inher-
ently non-traders, i.e. philosophically opposed to giving up any
amount of life in exchange for improved health. However, little
is known regarding characteristics associated with non-traders
or differences between traders and non-traders. METHODS: A
cross-sectional supervised self-administered survey was used to
assess the perception of health-related quality of life (HRQOL)
and utilities using the Time Trade-Off (TTO) method in the
general population of 3 groups: Caucasian Americans (n = 441),
African Americans (n = 344), Jamaicans (n = 41). Each person
was given one of three hypothetical health states. Logistic regres-
sion models were constructed and analyzed to investigate the
characteristics associated with being a non-trader. Independent
variables were age, gender, race/ethnicity, and importance of reli-
gion. We adjusted for current health. RESULTS: Of the 823 par-
ticipants, 17% were non-traders and 57% were female. Four
percent had not completed high school, 69% had a high school
degree and 27% had a college degree. In terms of importance of
religion, 3% reported that religion was not at all important, 6%
said religion was a little important, 23% said somewhat impor-
tant, and 68% said very important. Mean age of the population
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was 38 years. Age and importance of religion were signiﬁcant
predictors of non-trader status. People of younger age, age group
18 to 25 years (OR = 0.97, p = 0.0345) and those who placed
a higher importance on religion in their lives (OR = 5.08, p =
0.0131) were more likely to be non-traders. Gender and race/
ethnicity had no association. CONCLUSIONS: Younger age and
greater importance of religion in a person’s life were signiﬁcantly
associated with being predictors of non-trader status.
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OBJECTIVE: Patients’ perceptions of the value of their
antiepileptic medications are important factors in assessing
antiepileptic drug therapy. We developed and validated a scale
to combine patient-reported efﬁcacy, convenience and tolerabil-
ity of antiepileptic pharmacotherapy into a single measure of
overall usefulness. METHODS: Neurologists in two practices
assigned patients a priori to either a “doing well” or “not doing
well” group based upon clinical assessment of efﬁcacy, tolera-
bility and convenience of each patient’s antiepileptic medication.
Adult outpatients on antiepileptic medications completed a four-
item self-administered questionnaire. Patients scored the over-
all usefulness, efﬁcacy, tolerability and convenience of their
antiepileptic pharmacotherapy on visual analogue scales ranging
from 0 to 100. Fisher’s exact test was used to determine sys-
tematic differences in demographic characteristics or neurolo-
gist’s assessment of the two groups. Differences between groups
in mean overall usefulness and component scores were assessed
using the t-test. A multivariate model was used to assess weights
of efﬁcacy, tolerability and convenience on the overall usefulness
score. RESULTS: Sixty patients completed the questionnaire.
Sixty percent (60%) were classiﬁed as “doing well” and 24
(40%) as “not doing well” a priori on antiepileptic medication.
Both groups had similar demographic characteristics. The “not
doing well” group had signiﬁcantly more problems with efﬁcacy,
tolerability and convenience than the “doing well” group (p <
0.001). The mean overall usefulness score was higher for the
“doing well” group (88) compared to the “not doing well” group
(53) even after controlling for all demographic variables (p <
0.0001). Similar results were observed for efﬁcacy and tolera-
bility scores. No individual domain (efﬁcacy, tolerability, conve-
nience) had a disproportionate inﬂuence on the overall usefulness
score. CONCLUSIONS: This patient-reported usefulness scale
for antiepileptic drug therapy has potential application in
research and clinical settings to discriminate between patients
whose antiepileptic pharmacotherapy is efﬁcacious, tolerable
and convenient and those whose antiepileptic pharmacotherapy
is not.
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OBJECTIVE: The impact on health economic outcomes of using
either Framingham or United Kingdom Prospective Diabetes
Study (UKPDS) risk equations for stroke and myocardial infarc-
tion (MI) was evaluated. The effects of interventions aimed at
lipid proﬁle improvement, blood pressure control, or improved
glycemic control were modeled in typical type 2 diabetes cohorts
using either the Framingham or the UKPDS risk formulae
embedded in a documented, validated type-2 diabetes simulation
model. METHODS: The progression of diabetes complications
including both micro- and macrovascular disease was simulated.
Total lifetime costs/patient (TC), life expectancy (LE), and
costs/life-year gained (C/LYG) of 3 hypothetical interventions
affecting either lipid proﬁle (LDL lowered from 150–120mg/dl
and HDL raised from 35 to 45mg/dl costing $300/year/patient),
blood pressure (systolic blood pressure reduced from 170 to 140
mmHg costing $300/year), or glycemic control (HbA1c lowered
from 10 to 8.5%, costing $300/year) were calculated. RESULTS:
Using Framingham formulae consistently underestimated
improvements in LE when compared to using UKPDS formulae.
Due to the interplay of a number of factors, effects on TC and
C/LYG were less consistent. In the lipid-intervention, LE
improved by 0.41 years using Framingham formulae, and by
0.74 years using UKPDS. TC were increased by ~ $3400/patient
using both sets of formulae, but C/LYG were $13,094 using
Framingham and $7103 using UKPDS. In the blood pressure
intervention, LE improved 0.40 or 0.52 years using Framingham
formulae or UKPDS respectively. TC were decreased by around
$5814/patient using Framingham, and by $6591 using UKPDS.
In the glycemic control intervention, LE improve 0.37 years
using Framingham formulae, and by 0.66 years using UKPDS.
TC were decreased by $20,072/patient and by $4948 using
Framingham or UKPDS respectively, but C/LYG were $13,094
using Framingham and $7103 using UKPDS. CONCLUSIONS:
The choice of cardiovascular disease risk formulae has an impor-
tant impact on long term health economic outcomes of type-2
diabetes patients, and the predicted cost effectiveness of 
interventions.
(For abstract DB2 see page 342) HM1
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OBJECTIVES: In the past contradictory results on the effective-
ness of various disease management programs (DMP) for 
Diabetes mellitus (D.m.) have been reported. Beyond the chosen
care process, it seems particularly important to select only those
patients with the highest probability to beneﬁt from such a
program by risk stratiﬁcation to optimize the effectiveness
(patient outcome) and efﬁciency of DMPs. Here, a new method
is presented to stratify cohorts and identify patients using indi-
vidualized predictions with the D.m. disease model Mellibase.
METHODS: A Markov based disease model was used to calcu-
late individual expected medical and economic outcomes (ﬁve
typical complications of D.m) for 121 real-life cases on the basis
of baseline clinical parameters like HbA1c, blood pressure and
lipid levels. Two kinds of parameters were then used to select
one third of all cases: 1) Clinical parameters (those cases with
the worst values), and 2) computed parameters like life-
expectancy (those cases with the highest theoretical potential for
improvement). All stratiﬁcation parameters were then tested for
actual improvement of outcomes with real pre-post data taken
from a German DMP with type-2-diabetics. RESULTS: A strat-
